Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05959291 · ClinicalTrials.gov registry record · NA
Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
A NA study of Stage IV Breast Cancer and HER2-positive Metastatic Breast Cancer, sponsored by University of Miami.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05959291 is a NA study of Stage IV Breast Cancer and HER2-positive Metastatic Breast Cancer that is actively recruiting participants, run by University of Miami. The registered enrollment target is 20 participants, below the 66-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05959291, a NA study of Stage IV Breast Cancer and HER2-positive Metastatic Breast Cancer, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this preliminary research study is to see if patients discontinuing maintenance Herceptin and/or other anti-HER-2 treatments with monitoring in addition to radiologic imaging and routine blood work will stay in complete radiological remission and to determine how long patients are able to stay in complete radiological remission without treatment.
Conditions Studied
Interventions
- OTHER Discontinuation of Anti-HER-2 Maintenance Treatment
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-07-17 |
| Est. Completion | 2029-07-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05959291
The ClinicalTrials.gov registry entry for NCT05959291 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 66-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (70% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stage IV Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Discontinuation of Anti-HER-2 Maintenance Treatment is the first listed.
NCT05959291 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05959291 about?
NCT05959291 is a clinical study titled "Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer". The purpose of this preliminary research study is to see if patients discontinuing maintenance Herceptin and/or other anti-HER-2 treatments with monitoring in addition to radiologic imaging and routine blood work will stay in complete radiological remission and to determine how long patients are abl...
What is the current status of trial NCT05959291?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2023-07-17. Estimated completion is 2029-07-31.
What conditions does trial NCT05959291 study?
This clinical trial studies the following conditions: Stage IV Breast Cancer, HER2-positive Metastatic Breast Cancer.
What interventions are being tested in trial NCT05959291?
The interventions under investigation include: Discontinuation of Anti-HER-2 Maintenance Treatment (OTHER).
Who is sponsoring clinical trial NCT05959291?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05959291 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
ACTIVE NOT RECRUITING · NA
-
Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer
ACTIVE NOT RECRUITING · NA
-
Ask Questions (ASQ):Implementation of a Communication Intervention
COMPLETED · NA
-
Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer
COMPLETED · NA
-
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
COMPLETED · NA
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.